Prevent and Reverse Obesity in Children, Adolescents and Young Adults

The study will enroll 200 adults overweight or obese patients (balanced by sex) attending the metabolic diseases outpatient clinic.

The MeD effects on the reduction of cardiometabolic risk in overweight and obese individuals originate beyond the nutritional component. The combination of personalized dietary and lifestyle treatments in the MeD setting can result in a greater strategy to reduce overweight, obesity and related cardiometabolic risk factors than the MeD alone.

Therefore, in the present study reaserchers hypothesize that the MeD associated with personalized dietary, lifestyle, and therapeutic strategies, including digital tools, a physical activity program, and under-explored MeD components such as mushrooms and the Lebanese herbal mixture "Za'atar", can increase the diet efficacy in tackling overweight and obesity.

Primary Objective: To identify and validate personalized interventions (tailored to individual risk) aimed at reducing health risks associated with overweight and obesity by targeting environmental, socio-cultural, and metabolic health determinants responsible for fat accumulation and related systemic diseases.

Secondary Objectives: To evaluate the nutritional and functional benefits of personalized dietary/lifestyle strategies on pathogenic factors influencing metabolic and pro-inflammatory status and intestinal permeability.

Inclusion criteria

• 18-55 years old overweight or obese men and women (BMI ≥ 25 kg/m2).
• Signed informed consent.
• Have a mobile phone, tablet, or computer with internet access.

Exclusion criteria

• Waist circumference > 150 cm
• Suffer from diabetes or other disorders of glucose metabolism
• Suffer from dyslipidemia or other alterations of lipid metabolism (LDL cholesterol ≥ 189 mg/dL and/or triglycerides ≥ 350 mg/dL).
• Present chronic gastrointestinal problems such as Crohn's disease or irritable bowel syndrome.
• Present any chronic or autoimmune disease in clinical manifestation such as hepatitis, hyper or hypothyroidism or metabolic diseases.
• Have a diagnosed liver disease other than steatotic liver disease.
• Taking supplements or multivitamin supplements or phototherapeutic products for weight loss that interfere with the study.
• Have taken antibiotics in the last 30 days.
• Follow a low-calorie diet and/or pharmacological treatment for weight loss.
• Being a smoker.
• Regular alcohol consumption (more than 4 Standard Drink Units (SDU) per day or 28 SDU per week.
• Have lost more than 3 kg of weight in the last 3 months.
• Suffering from eating disorders or psychiatric disorders.
• Present food intolerances and/or allergies related to the study products, such as allergy to edible mushrooms or fungal spores or to any of the components of the Lebanese herbal mixture Za'atar such as sesame seeds.
• Be pregnant or intend to become pregnant or be breastfeeding,
• Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study.
• No or limited access to the Internet.